HomeCompareCNPAY vs ABBV

CNPAY vs ABBV: Dividend Comparison 2026

CNPAY yields 8.36% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNPAY wins by $1545.11M in total portfolio value
10 years
CNPAY
CNPAY
● Live price
8.36%
Share price
$11.29
Annual div
$0.94
5Y div CAGR
79.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1545.21M
Annual income
$1,447,164,778.76
Full CNPAY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CNPAY vs ABBV

📍 CNPAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNPAYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNPAY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNPAY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNPAY
Annual income on $10K today (after 15% tax)
$710.72/yr
After 10yr DRIP, annual income (after tax)
$1,230,090,061.95/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CNPAY beats the other by $1,230,069,005.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNPAY + ABBV for your $10,000?

CNPAY: 50%ABBV: 50%
100% ABBV50/50100% CNPAY
Portfolio after 10yr
$772.66M
Annual income
$723,594,775.26/yr
Blended yield
93.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CNPAY
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNPAY buys
0
ABBV buys
0
No recent congressional trades found for CNPAY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNPAYABBV
Forward yield8.36%3.06%
Annual dividend / share$0.94$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR79.5%40.6%
Portfolio after 10y$1545.21M$102.3K
Annual income after 10y$1,447,164,778.76$24,771.77
Total dividends collected$1538.05M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CNPAY vs ABBV ($10,000, DRIP)

YearCNPAY PortfolioCNPAY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,201$1,500.87$11,550$430.00+$651.00CNPAY
2$16,127$3,071.95$13,472$627.96+$2.7KCNPAY
3$24,067$6,811.68$15,906$926.08+$8.2KCNPAY
4$42,806$17,053.53$19,071$1,382.55+$23.7KCNPAY
5$96,684$50,882.30$23,302$2,095.81+$73.4KCNPAY
6$296,250$192,797.87$29,150$3,237.93+$267.1KCNPAY
7$1,308,014$991,026.24$37,536$5,121.41+$1.27MCNPAY
8$8,739,973$7,340,397.80$50,079$8,338.38+$8.69MCNPAY
9$91,632,472$82,280,700.98$69,753$14,065.80+$91.56MCNPAY
10$1,545,211,524$1,447,164,778.76$102,337$24,771.77+$1545.11MCNPAY

CNPAY vs ABBV: Complete Analysis 2026

CNPAYStock

CNP Assurances SA (ENXTPA:CNP) provides insurance, coinsurance, and reinsurance solutions in France, Latin America, and other European countries. It offers life, accident, long-term care, death and funerals, disability, unemployment, loss of income, health, and dental insurance products; property and casualty insurance, such as home-owner and auto insurance; term creditor and guarantee insurance products, including home and business loans, and consumer finance; solutions in the area of guarantees for real estate loans in private market; and pension plans, as well as support and assistance services. The company was founded in 1850 and is headquartered in Paris, France. CNP Assurances SA (ENXTPA:CNP) operates as a subsidiary of La Banque Postale S.A.

Full CNPAY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CNPAY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNPAY vs SCHDCNPAY vs JEPICNPAY vs OCNPAY vs KOCNPAY vs MAINCNPAY vs JNJCNPAY vs MRKCNPAY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.